Atom | Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed)

Due Dates: April 7, 2025 (Open) | May 7, 2025 | September 7, 2025 | January 7, 2026 | February 18, 2026 (Final closing)

Funding Amounts: Up to $275,000 direct costs over 2 years; no more than $200,000 in any single year.

Summary: Supports exploratory research on how HIV-induced immunometabolic changes in cART-suppressed individuals impact risk and outcomes for TB or HBV co-infection.

Key Information: Clinical trials are not allowed; applications must focus on HIV-associated immunometabolic changes with TB or HBV co-infection.

Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed)

Sign in to see full grant listing